Provided by Tiger Trade Technology Pte. Ltd.

Xencor

24.84
+0.07000.28%
Post-market: 25.230.3900+1.57%19:41 EDT
Volume:1.10M
Turnover:27.18M
Market Cap:1.84B
PE:-11.41
High:25.50
Open:25.36
Low:24.14
Close:24.77
52wk High:30.61
52wk Low:10.38
Shares:74.13M
Float Shares:54.25M
Volume Ratio:0.79
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1768
EPS(LYR):-1.2400
ROE:-29.07%
ROA:-16.83%
PB:3.66
PE(LYR):-20.03

Loading ...

Wells Fargo Reaffirms Their Buy Rating on Xencor (XNCR)

TIPRANKS
·
Sep 30

Xencor Price Target Raised to $29.00/Share from $27.00 by Truist Securities

Dow Jones
·
Sep 28

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and IQVIA Holdings (IQV)

TIPRANKS
·
Sep 28

Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says

MT Newswires Live
·
Sep 26

BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating

MT Newswires Live
·
Sep 21

Xencor price target raised to $26 from $20 at BofA

TIPRANKS
·
Sep 21

Xencor is Maintained at Overweight by Barclays

Dow Jones
·
Sep 11

Xencor price target raised to $35 from $27 at Barclays

TIPRANKS
·
Sep 11

Xencor (XNCR) Receives a Buy from Barclays

TIPRANKS
·
Sep 11

Xencor price target raised to $21 from $14 at JPMorgan

TIPRANKS
·
Sep 03

Xencor (XNCR) Could Be 6% Below Fair Value On Its Antibody Pipeline Narrative

Simply Wall St.
·
Sep 03

Xencor to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 03

Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating

MT Newswires Live
·
Sep 01

Xencor Advances Dual-Antibody Cancer Trial, Keeping Investor Focus on XNCR

TIPRANKS
·
Aug 14

Analysts’ Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)

TIPRANKS
·
Aug 10

Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio

Reuters
·
Aug 08

Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense

Reuters
·
Aug 07

Verastem Q2 Revenue Jumps on New Product Sales and Milestone

Reuters
·
Aug 07

Xencor Price Target Raised to $30.00/Share from $26.00 by Wedbush

Dow Jones
·
Aug 06

Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook

Reuters
·
Aug 06